With the health and safety of members, volunteers, and attendees in mind, SNMMI made the decision to reschedule the SNMMI Therapeutics Conference, originally scheduled for November 11-13, 2021. The SNMMI Therapeutics Conference will now take place March 10-12, 2022, in New Orleans, LA. Read the full date change announcement.
SNMMI members can save 50% when they register to attend SNMMI's Online Nuclear Medicine Review Course and in-training resident members can register for free. This two-day course is the perfect resource to help you prepare for your board exam or use as a great general refresher to enhance your practice! Register.
ACNM Annual Meeting abstract submission window opens in September. Sign up to be contacted when more information becomes available for 2022 SNMMI Mid-Winter and ACNM Annual Meeting.
Welcome to our Healthcare Provider portal. Everything you need to understand the advantages and applications of nuclear medicine and molecular imaging in your practice. Find out more about ordering the right test for the right patient at the right time.
Appropriate Use Criteria (AUC) are statements that contain indications describing when, and how often, an intervention should be performed under the auspices of scientific evidence, clinical judgment, and patient values while avoiding unnecessary provisions of services. SNMMI follows a balanced multidisciplinary approach to guidance development by including various stakeholders in the development process. To view the development process, please click the following link: SNMMI AUC Development Process.
SNMMI has created guidelines to identify those elements of the procedure that are most important in obtaining a high-quality examination, Appropriate Use Criteria (AUC), and is working towards optimizing dose.
Appropriate Use Criteria
NCCN's Guidelines Tabular Summary
NCCN Practice Guidelines Narrative Summary
The SNMMI PET Center of Excellence has created a go-to resource with in-depth ordering information and printable materials related to PET and PET/CT, including:
SNMMI is dedicated to providing the community with access to the most knowledgeable and experienced speakers in the field of nuclear medicine and molecular imaging. As part of the new Outreach Program, SNMMI is working to enhance relationships with relevant societies and patient organizations. We have created a pool of speakers who can speak at your next meeting. Please complete the form below to request a speaker.
Outreach Speaker Request Form
A new meta-analysis indicates that amino acid PET can accurately differentiate recurrent or progressive brain metastases from treatment-related changes, potentially reducing overtreatment, according to research published in May JNM.
Two articles in the May issue of JNM illustrate the promise of the novel FAPI radiotracer. Results from the largest study of patients undergoing 68Ga-FAPI PET demonstrate the superiority of 68Ga-FAPI over standard 18F-FDG PET in evaluating multiple types of cancer. In a separate study, a newly designed FAPI-targeted treatment was found to suppress tumor growth in several common cancers in a preclinical setting. These advances have strong potential to provide more precise staging and management for cancer patients.
International, multicenter testing demonstrated the effectiveness of a newly established PSMA PET scoring system that can successfully predict whether metastatic castration-resistant prostate cancer patients will respond to treatment with Lu-177 PSMA therapy. The research was published online in JNM.
SNMMI and 10 other professional societies have issued appropriate use criteria for lymphoscintigraphy in sentinel node mapping and lymphedema/lipedema. The criteria are summarized in the April issue of JNM.
SNMMI monitors multiple federal legislative issues and provides resources including issue summaries, letters to Congress, and analysis. Most of this information is in the government relations news section of this web site.
Happy Nuclear Medicine Week! Encourage community members to take pride in their profession – recognizing their colleagues for their hard work and promoting nuclear medicine to the entire medical community as well as to the public.